Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540749 | 0.85 | GRM5 (0.67) | GRM5MEN1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4536917 | 0.85 | GRM5 (0.67) | GRM5MEN1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4539141 | 0.85 | GRM5 (0.67) | GRM5MEN1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4538662 | 0.85 | GRM5 (0.67) | GRM5MEN1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL16319384 | 0.85 | GRM5 (0.67) | GRM5MEN1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5021486 | 0.84 | GRM5 (0.58) | GRM5MEN1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13642272 | 0.84 | GRM5 (0.66) | GRM5 | |
| SCHEMBL13642271 | 0.84 | GRM5 (0.66) | GRM5 | |
| SCHEMBL4536796 | 0.84 | GRM5 (0.64) | GRM5CYP2D6 | |
| SCHEMBL5021369 | 0.83 | GRM5 (0.61) | GRM5MEN1CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| EP-2638022-B1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL MYERS SQUIBB CO (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8691821-B2 | Oxazolidinones as modulators of mGluR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691821-B2 | Oxazolidinones as modulators of mGluR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2638022-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | Bristol-Myers Squibb Company (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
| WO-2012064603-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283264-A1 | Oxazolidinones as Modulators of MGLUR5 | GRM5, GRIK5, GRM1 | GRM5 1/4885MEN1 4226/4885CYP3A4 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.